4.8 Article

The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells

期刊

GUT
卷 64, 期 12, 页码 1936-1948

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2014-308470

关键词

-

资金

  1. ERC [Pa-CSC 233460]
  2. European Community [256974, 602783]
  3. Subdireccion General de Evaluacion y Fomento de la Investigacion
  4. Fondo de Investigacion Sanitaria [PS09/02129, PI12/02643]
  5. Programa Nacional de Internacionalizacion de la I+D, Subprogramma: FCCI (Ministerio de Economia y Competitividad, Spain) [PLE2009-0105]
  6. La Caixa Predoctoral Fellowship

向作者/读者索取更多资源

Objective Cancer stem cells (CSCs) represent the root of many solid cancers including pancreatic ductal adenocarcinoma, are highly chemoresistant and represent the cellular source for disease relapse. However the mechanisms involved in these processes still need to be fully elucidated. Understanding the mechanisms implicated in chemoresistance and metastasis of pancreatic cancer is critical to improving patient outcomes. Design Micro-RNA (miRNA) expression analyses were performed to identify functionally defining epigenetic signatures in pancreatic CSC-enriched sphere-derived cells and gemcitabine-resistant pancreatic CSCs. Results We found the miR-17-92 cluster to be downregulated in chemoresistant CSCs versus non-CSCs and demonstrate its crucial relevance for CSC biology. In particular, overexpression of miR-17-92 reduced CSC self-renewal capacity, in vivo tumourigenicity and chemoresistance by targeting multiple NODAL/ACTIVIN/TGF-beta 1 signalling cascade members as well as directly inhibiting the downstream targets p21, p57 and TBX3. Overexpression of miR-17-92 translated into increased CSC proliferation and their eventual exhaustion via downregulation of p21 and p57. Finally, the translational impact of our findings could be confirmed in preclinical models for pancreatic cancer. Conclusions Our findings therefore identify the miR-17-92 cluster as a functionally determining family of miRNAs in CSCs, and highlight the putative potential of developing modulators of this cluster to overcome drug resistance in pancreatic CSCs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma

Marta Alonso-Nocelo, Laura Ruiz-Canas, Patricia Sancho, Kivanc Gorgulu, Sonia Alcala, Coral Pedrero, Mireia Vallespinos, Juan Carlos Lopez-Gil, Marina Ochando, Elena Garcia-Garcia, Sara Maria David Trabulo, Paola Martinelli, Patricia Sanchez-Tomero, Carmen Sanchez-Palomo, Patricia Gonzalez-Santamaria, Lourdes Yuste, Sonja Maria Wormann, Derya Kabacaoglu, Julie Earl, Alberto Martin, Fernando Salvador, Sandra Valle, Laura Martin-Hijano, Alfredo Carrato, Mert Erkan, Laura Garcia-Bermejo, Patrick C. Hermann, Hana Algul, Gema Moreno-Bueno, Christopher Heeschen, Francisco Portillo, Amparo Cano, Bruno Sainz

Summary: LOXL2 plays an important role in pancreatic ductal adenocarcinoma (PDAC), with its loss inhibiting metastasis and prolonging overall survival, while overexpression promotes tumor growth and decreases overall survival. Macrophage-secreted OSM is an inducer of LOXL2 expression, with targeting macrophages affecting its expression and collagen fiber alignment.
Article Medicine, Research & Experimental

Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma

Beatriz Parejo-Alonso, Alba Royo-Garcia, Pilar Espiau-Romera, Sarah Courtois, Alvaro Curiel-Garcia, Sladjana Zagorac, Isabel Villaoslada, Kenneth P. Olive, Christopher Heeschen, Patricia Sancho

Summary: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by metastasis and chemoresistance. Targeting the ALK signaling pathway can decrease tumor formation and chemoresistance in PDAC by inhibiting pancreatic cancer stem cells.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Article Immunology

Mast cells impair melanoma cell homing and metastasis by inhibiting HMGA1 secretion

Alberto Benito-Martin, Laura Nogues, Marta Hergueta-Redondo, Elena Castellano-Sanz, Eduardo Garvin, Michele Cioffi, Paloma Sola-Castrillo, Weston Buehring, Pilar Ximenez-Embun, Javier Munoz, Irina Matei, Josep Villanueva, Hector Peinado

Summary: Metastatic disease is a leading cause of cancer-related deaths. Mast cells, a type of immune cells, play a crucial role in the formation of pre-metastatic niche. Surprisingly, mast cells have both pro-metastatic and anti-metastatic effects, as shown in in vivo and in vitro studies. The expression and secretion of HMGA1 in melanoma cells are associated with metastatic behavior, and targeting HMGA1 can reduce melanoma metastasis. These findings provide insights into the potential use of HMGA1 as a therapeutic target in melanoma.

IMMUNOLOGY (2023)

Article Oncology

Dissecting the role of toll-like receptor 7 in pancreatic cancer

Maren Stark, Marina Nicolai, Marina Tatura, Corinna U. Keber, Andreas Kaufmann, Ho-Ryun Chung, Emily P. Slater, Christopher Heeschen, Rita T. Lawlor, Aldo Scarpa, Detlef K. Bartsch, Thomas M. Gress, Stefan Bauer, Malte Buchholz

Summary: TLR7 is overexpressed in PDAC and is associated with shorter patient survival. Inhibition of TLR7 reduces cell viability in PDAC cell lines. However, global TLR7 deficiency does not affect survival or overall histopathological tumor features in PDAC mouse models.

CANCER MEDICINE (2023)

Review Biochemistry & Molecular Biology

Liquid biopsy in pancreatic cancer-Current perspective and future outlook

Yaru Zhao, Jiajia Tang, Ke Jiang, Shin-Yi Liu, Alexandra Aicher, Christopher Heeschen

Summary: Pancreatic cancer is a deadly disease with increasing incidence and late-stage presentation, resulting in low survival rates. The lack of specific symptoms, biomarkers, and screening tools hinders early diagnosis. Liquid biopsies have emerged as a non-invasive and repeatable method for sampling and analyzing circulating tumor cells, small extracellular vesicles, and tumor DNA. Although liquid biopsies have the potential to aid in early detection, risk stratification, and precision medicine in pancreatic cancer, they have not yet become a routine tool for clinicians. This article summarizes recent findings on the use of liquid biopsy in pancreatic cancer patients, discussing current challenges and future perspectives on this potentially powerful alternative to conventional tissue biopsies.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2023)

Article Oncology

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway

Jonas Althaus, Verena Nilius-Eliliwi, Abdelouahid Maghnouj, Sascha Doering, Roland Schroers, Michael Hudecek, Stephan A. Hahn, Thomas Mika

Summary: Chimeric antigen receptors (CARs) have been effective in improving cancer immunotherapy, especially using immune cells like NK cells or T cells as effector cells. NK92 cells, a cell line with known cytotoxic activity, are particularly promising in CAR therapy due to their simplicity in culturing conditions and proven anti-tumor efficacy with a manageable safety profile. Understanding the cytotoxic mechanisms of CAR effector cells is crucial in uncovering potential resistance mechanisms, especially in lymphoma cases with frequent apoptosis pathway mutations. This study found that the perforin/granzyme pathway is the major pathway mediating cytotoxicity in CD19-CAR-NK92 cells, as knockout of perforin 1 significantly reduced their cytotoxicity.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Review Oncology

Single-cell omics: a new perspective for early detection of pancreatic cancer?

Qi Wang, Berina Sabanovic, Azhar Awada, Chiara Reina, Alexandra Aicher, Jiajia Tang, Christopher Heeschen

Summary: Pancreatic cancer is a deadly disease with limited treatment options due to late diagnosis. Liquid biopsies, particularly circulating tumor cells (CTCs) and their single-cell omics analysis, have the potential to detect pancreatic cancer early and provide valuable molecular insights. CTCs offer comprehensive genomic, transcriptomic, epigenetic, and proteomic information that can help understand tumor heterogeneity and track cancer features. The emerging technology of ex vivo culturing of CTCs could enable the study of individual cancers and the development of personalized treatment approaches.

EUROPEAN JOURNAL OF CANCER (2023)

Article Gastroenterology & Hepatology

Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer

Feda H. Hamdan, Amro M. Abdelrahman, Ana Patricia Kutschat, Xin Wang, Thomas L. Ekstrom, Nidhi Jalan-Sakrikar, Catherine Wegner Wippel, Negar Taheri, Liezel Tamon, Waltraut Kopp, Joana Aggrey-Fynn, Aditya Bhagwate, Roberto Alva-Ruiz, Isaac Lynch, Jennifer Yonkus, Robyn Laura Kosinsky, Jochen Gaedcke, Stephan A. Hahn, Jens T. Siveke, Rondell Graham, Zeynab Najafova, Elisabeth Hessmann, Mark J. Truty, Steven A. Johnsen

Summary: This study discovered a group of enhancers called iHUBs, which are involved in transcriptional reprogramming and chemoresistance in pancreatic ductal adenocarcinoma (PDAC). Inhibiting or deleting iHUBs can decrease the transcription of target genes and sensitize resistant cells to chemotherapy. Targeting eRNA production or signaling pathways upstream of iHUB activation can restore chemotherapy responsiveness in vitro and in vivo.
Article Oncology

Identification of a DNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma

Xin Wang, Ana P. Kutschat, Joana Aggrey-Fynn, Feda H. Hamdan, Rondell P. Graham, Alexander Q. Wixom, Yara Souto, Swetlana Ladigan-Badura, Jennifer A. Yonkus, Amro M. Abdelrahman, Roberto Alva-Ruiz, Jochen Gaedcke, Philipp Stroebel, Robyn Laura Kosinsky, Florian Wegwitz, Patrick Hermann, Mark J. Truty, Jens T. Siveke, Stephan A. Hahn, Elisabeth Hessmann, Steven A. Johnsen, Zeynab Najafova

Summary: The lack of molecular stratification approaches and targeted therapy is a major hurdle in applying precision oncology to pancreatic cancer. This study aimed to identify molecular and epigenetic signatures of a specific subclass of pancreatic ductal adenocarcinoma (PDAC) and validate their application for patient stratification and therapy monitoring. By analyzing gene expression and epigenome mapping data, the researchers identified subtype-specific enhancer regions and successfully confirmed the validity of enhancer RNA (eRNA) detection as a histologic approach for patient stratification. This study provides proof-of-concept that single-cell level detection of subtype-specific epigenetic changes is possible in complex primary tumor material.

MOLECULAR CANCER RESEARCH (2023)

Article Pharmacology & Pharmacy

An Aptamer against MNK1 for Non-Small Cell Lung Cancer Treatment

Rebeca Carrion-Marchante, Celia Pinto-Diez, Jose Ignacio Klett-Mingo, Esther Palacios, Miriam Barragan-Usero, M. Isabel Perez-Morgado, Manuel Pascual-Mellado, Sonia Alcala, Laura Ruiz-Canas, Bruno Sainz Jr, Victor M. Gonzalez, M. Elena Martin

Summary: Lung cancer is a major cause of cancer-related death worldwide. A previously identified aptamer, apMNKQ2, showed promising results as an antitumor drug in breast cancer. This study investigates the antitumor potential of apMNKQ2 in non-small cell lung cancer where MNK1 plays a significant role.

PHARMACEUTICS (2023)

Article Cell Biology

GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells

Britta Majchrzak-Stiller, Marie Buchholz, Ilka Peters, Daniel Waschestjuk, Johanna Strotmann, Philipp Hoehn, Stephan Hahn, Chris Braumann, Waldemar Uhl, Thomas Mueller, Hanns Moehler

Summary: GP-2250, a novel anticancer agent, inhibits energy metabolism by targeting hexokinase 2 and glyceraldehyde-3-phosphate dehydrogenase, resulting in a decrease in ATP level. It causes cytotoxicity primarily through a deficit in the tricarboxylic acid cycle, leading to impaired synthesis of fatty acids and proteins. In addition, GP-2250 disrupts NF-κB signaling, reducing tumour cell proliferation and promoting apoptosis.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2023)

Article Oncology

Lasting response by vertical inhibition with cetuximab and trametinib in KRAS-mutated colorectal cancer patient-derived xenografts

Timm M. Reissig, Swetlana Ladigan-Badura, Anja Steinberg, Abdelouahid Maghnouj, Ting Li, Berlinda Verdoodt, Sven T. Liffers, Michael Pohl, Heiner Wolters, Christian Teschendorf, Richard Viebahn, Jakob Admard, Nicolas Casadei, Andrea Tannapfel, Wolff Schmiegel, Stephan A. Hahn, Deepak B. Vangala

Summary: This study investigated the efficacy of vertical inhibition of the RAS-pathway in patient-derived xenograft tumors with primary KRAS mutation. The results showed that vertical inhibition therapy induced stable disease or partial response in the majority of models, with long-lasting responses and a low incidence of secondary resistance. Molecular analysis revealed that transcriptional reprogramming activating the RAS pathway drove primary and secondary resistance in a substantial fraction of tumors.

MOLECULAR ONCOLOGY (2023)

Article Biochemistry & Molecular Biology

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer

Pashtoon Murtaza Kasi, Manuel Hidalgo, Mehraneh D. Jafari, Heather Yeo, Lea Lowenfeld, Uqba Khan, Alana T. H. Nguyen, Despina Siolas, Brandon Swed, Jini Hyun, Sahrish Khan, Madeleine Wood, Benjamin Samstein, Juan P. Rocca, Allyson J. Ocean, Elizabeta C. Popa, Daniel H. Hunt, Nikhil P. Uppal, Kelly A. Garrett, Alessio Pigazzi, Xi Kathy Zhou, Manish A. Shah, Erika Hissong

Summary: This study reports exceptional responses observed in patients with pMMR/MSS colon and rectal cancer treated with neoadjuvant botensilimab (BOT) and balstilimab (BAL). The findings have important implications for clinical trial designs using neoadjuvant immunotherapy and potentially sparing patients chemotherapy.

ONCOGENE (2023)

Article Obstetrics & Gynecology

Prediction of recurrent gestational diabetes mellitus: a retrospective cohort study

Stephan Hahn, Sabine Koerber, Bernd Gerber, Johannes Stubert

Summary: Background: Women after gestational diabetes mellitus (GDM) are at increased risk for development of GDM recurrence. Objective: To evaluate factors for prediction of risk of recurrence. Methods: Retrospective cohort study including 159 women with GDM and a subsequent pregnancy. Logistic regression models were used to analyze putative risk factors for GDM recurrence. Results were compared to age-matched women without GDM. Results: The overall risk of GDM recurrence was 72.3%. Risk factors for recurrence included high pregravid BMI, positive family history, and insulin treatment during the index pregnancy. Cesarean section delivery (index pregnancy) showed borderline significance. Interpregnancy weight gain, excessive weight gain during the index pregnancy, and fetal outcome were not predictive. Neonates after GDM had a higher frequency of transfer to intensive care unit compared to controls. The best combined risk model for prediction of GDM recurrence included positive family history and high pregravid BMI. Conclusions: Positive family history of diabetes mellitus with overweight or obesity increases the risk of GDM recurrence. Normalization of pregravid BMI is an effective approach to reduce the risk of GDM recurrence.

ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2023)

Article Biochemistry & Molecular Biology

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer

Pashtoon Murtaza Kasi, Manuel Hidalgo, Mehraneh D. Jafari, Heather Yeo, Lea Lowenfeld, Uqba Khan, Alana T. H. Nguyen, Despina Siolas, Brandon Swed, Jini Hyun, Sahrish Khan, Madeleine Wood, Benjamin Samstein, Juan P. Rocca, Allyson J. Ocean, Elizabeta C. Popa, Daniel H. Hunt, Nikhil P. Uppal, Kelly A. Garrett, Alessio Pigazzi, Xi Kathy Zhou, Manish A. Shah, Erika Hissong

Summary: Neoadjuvant botensilimab and balstilimab showed exceptional responses in patients with locally advanced mismatch repair proficient/microsatellite stable colon and rectal cancer. The observed rapid immune response pattern has not been previously described. Spatial biology analyses revealed the mechanism of action of botensilimab.

ONCOGENE (2023)

暂无数据